CombinatoRx Oncology Programs to Be Highlighted at ASH 2009.Preclinical Data on A2A and Beta-2 Adrenergic Receptor adrenergic receptor n. Any of several reactive components of effector tissues most of which are innervated by adrenergic postganglionic fibers of the sympathetic nervous system and are activated by norepinephrine, epinephrine, and various adrenergic Agonist Programs in B-Cell Malignancies To Be Presented CAMBRIDGE, Mass. -- CombinatoRx, Incorporated (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRXX) today announced that two abstracts highlighting data on its A2A and Beta-2 Adrenergic Receptor Agonist oncology programs have been accepted for presentation at the American Society for Hematology (ASH) 2009 Annual Meeting in New Orleans on December 5-8, 2009. Poster Presentation: * Abstract #3762, Poster Board III-698, Monday, December 7, 2009, 6:00 PM-8:00 PM, "Adenosine adenosine /aden·o·sine/ (ah-den´o-sen) a purine nucleoside consisting of adenine and ribose; a component of RNA. It is also a cardiac depressant and vasodilator used as an antiarrhythmic and as an adjunct in myocardial perfusion imaging A2A and Beta-2 Adrenergic Receptor Agonist Synergy in B-Cell Malignancies: Selectivity, Breadth of Activity and Effects of Chronic Exposure", Rickles, et.al., Ernest N. Morial Convention Center The Ernest N. Morial Convention Center is a collection of buildings in New Orleans, Louisiana. The lower end of building one is located 500 m (1640 feet) upriver from Canal Street on the banks of the Mississippi River. Named after former mayor of New Orleans Ernest N. , Hall E. * Abstract #3831, Poster Board III-767, Monday, December 7, 2009, 6:00 PM-8:00 PM, "A2A or Beta-2 Adrenergic Receptor Agonist Synergies Induce Distinct Patterns of Gene Expression Relevant to Multiple Myeloma myeloma /my·elo·ma/ (mi?e-lo´mah) a tumor composed of cells of the type normally found in the bone marrow. giant cell myeloma see under tumor (1). Cell Survival", Rickles, et.al., Ernest N. Morial Convention Center, Hall E. About CombinatoRx CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action, striking at the biological complexities of human disease. The CombinatoRx proprietary drug discovery technology provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx, please visit www.combinatorx.com. Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 concerning CombinatoRx and its B-cell malignancy programs. These forward-looking statements about future expectations, plans and prospects of CombinatoRx, and its B-cell malignancy programs involve significant risks, uncertainties and assumptions, including risks related to CombinatoRx's ability to further develop and obtain regulatory approval for its B-cell malignancy programs and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. These forward looking statements reflect management's current views and CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release. (c) 2009 CombinatoRx, Incorporated. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion